ArticleThe world journal of men's health2026
Efficacy of
Article in The world journal of men's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeLower urinary tract symptoms (LUTS) in men substantially impair quality of life and are commonly treated with alpha-blockers or 5-alpha reductase inhibitors, which may cause adverse effects. MATERIALS AND
methodsIn this randomized, double-blind, placebo-controlled trial, 100 men aged 40-80 years with moderate LUTS (International Prostate Symptom Score [IPSS] 8-19) were randomized to receive NET1701 (325 mg/d) or placebo for 12 weeks. The primary outcome was the change in total IPSS from baseline to 12 weeks. Secondary outcomes included IPSS subscores, maximum urinary flow rate (Qmax), post-void residual volume (PVR), serum testosterone levels, and safety.
resultsAt 12 weeks, the NET1701 group showed a significantly greater reduction in total IPSS compared with placebo (-5.67±3.86 vs. -1.00±4.30; p<0.0001). Significant improvements were observed in several IPSS subscores, including incomplete emptying, frequency, intermittency, and weak stream (p<0.05). Although Qmax and PVR did not differ significantly between groups, urinary symptom-related quality-of-life scores improved significantly in the NET1701 group (p<0.0001). NET1701 was well tolerated, with no severe adverse events reported.
conclusionsThe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.